Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) Equity Average (2016 - 2025)

Historic Equity Average for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to $67.4 million.

  • Niagen Bioscience's Equity Average rose 10721.65% to $67.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.4 million, marking a year-over-year increase of 10721.65%. This contributed to the annual value of $37.3 million for FY2024, which is 3049.64% up from last year.
  • Niagen Bioscience's Equity Average amounted to $67.4 million in Q3 2025, which was up 10721.65% from $59.8 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Equity Average registered a high of $67.4 million during Q3 2025, and its lowest value of $20.9 million during Q3 2022.
  • For the 5-year period, Niagen Bioscience's Equity Average averaged around $34.7 million, with its median value being $28.8 million (2022).
  • As far as peak fluctuations go, Niagen Bioscience's Equity Average tumbled by 4612.65% in 2022, and later surged by 10721.65% in 2025.
  • Niagen Bioscience's Equity Average (Quarter) stood at $33.6 million in 2021, then fell by 26.02% to $24.8 million in 2022, then grew by 12.21% to $27.9 million in 2023, then surged by 44.29% to $40.2 million in 2024, then skyrocketed by 67.62% to $67.4 million in 2025.
  • Its Equity Average stands at $67.4 million for Q3 2025, versus $59.8 million for Q2 2025 and $50.7 million for Q1 2025.